Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials - investor.lilly.com
Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials investor.lilly.com Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial Nature Daily pill to help keep weight off after stopping obesity jabs BBC Patients don't regain much weight switching from injections to Lilly's weight-loss pill, study finds Reuters Quitting weight-loss drugs or a diet can cause weight regain—two strategies could help prevent that Scientific American
YesNo saves this item as an on-site live signal so search users can understand how it connects to prediction markets and incubation topics.
If later reporting creates a clear deadline, official source, or verifiable outcome, the public event can become a tradable Yes/No question.
This item has a verifiable event angle that can be monitored for a Yes/No prediction market.